Shin-Etsu Chemical has developed new process technologies, transfer parts and other equipment for Micro LED displays
2.2.2023 09:00:00 EET | Business Wire | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed new process technologies that can be applied for the manufacturing of Micro LED displays.
The size of a Micro LED chip is not visible to the naked eye, with the length of one side being less than 50 μm (micrometers). For example, in order to manufacture one 4K display that has 4 times the resolution of a conventional high-definition screen, it is necessary to precisely array about 24.90 million chips. In order to implement improvements in the complexity and yield ratio in the processes of Micro LED chip manufacturing and the transfer process of each chip, Shin-Etsu Chemical has been working together with Shin-Etsu Group companies to take advantage of our unique materials technologies. We have proceeded to develop various advanced innovative transfer equipment and transfer parts to solve the key manufacturing challenges of Micro LED display manufacturing.
The new process technologies we are announcing were jointly developed with Dexerials Corporation (Head Office: Shimotsuke City, Tochigi Prefecture, Japan; President: Yoshihisa Shinya) and introduces innovative technology that will transfer singulated anisotropic conductive film (ACF) of Φ80μm or less onto the targeted location by laser equipment. Employing this technology, it becomes possible to transfer the singulated ACF only to the designated plate and mount the Micro LED chip on it and makes the repair process in Micro LED display manufacturing easy to carry out, a matter which had been a large issue up until now.
In addition, in order to meet the requests of customers for such matters as achieving further improvements in productivity and in the handling of a wide variety of chips, working in cooperation with two Shin-Etsu Chemical Group companies, Shin-Etsu Engineering Co, Ltd (Head Office: Tokyo; President: Kenji Sugii) and Shin-Etsu Polymer Co., Ltd. (Head Office Tokyo; President: Yoshiaki Ono), Shin-Etsu Chemical developed the following transfer equipment and transfer parts and expanded our products line-up. Combining the advantages of these Shin-Etsu transfer equipment and transfer parts, we will be able to offer the most optimized manufacturing processes to our customers:
- SQDP-B Series, cure type donor plate
- EZ-PETAMP Series, multi-stage dot-type large stamp (6 inch)
- Invisi LUM-X4, a 4-in-1 system that makes it possible to perform 4 processes using 1 laser
-
BM encapsulant film for Mini LED displays
(For details, please refer to the attached reference material.)
Shin-Etsu Chemical, as a “One-stop Solution Provider” in Micro LED manufacturing, will propose to customers’ solutions to the key challenges presented in the manufacturing processes for Micro LED displays, and we will work to spread the popularity of next-generation Micro LED displays and to expand its position in the display market.
Reference Material
1. SQDP (Shin-Etsu Quartz Donor Plate) —B Series, curing type donor plate
We developed the SQDP-B Series of curing type donor plate that makes laser lift off of Micro LED chips with a solder bump possible. By heat curing after the LED wafer is bonded, it can prevent tilting and cracking of the chips. With this curing type donor plate, laser lift off became possible for Mini LED chips on which cracks can easily have occur and for InGaN (Indium Gallium Nitride) and quaternary system red color Micro LED chips.
2. EZ-PETAMP multi-stage pattern dot-type large stamp (6 inch)
In this way, because there is no interference around the periphery of the chips, it becomes possible to greatly narrow the spacing of the extraordinarily large volume of chips that are being relocated on the second donor plate — much narrower than the pixel pitch. At the same time, by using this product, selective pick up of the chips becomes easy and a remarkable improvement in throughput as well as a reduction of the second donor plate usage volume can be realized.
3. Invisi LUM-X4, a 4-in 1 system that can handle 4 processes with one laser
Shin-Etsu Engineering will market a compact system that integrates the 4 processes that use a laser into one: multi laser lift off, laser mass transfer and high-speed trimming/repair. Unlike the existing system for mass production, not only can all laser processes, from chip singulation to mass transfer and trimming and repair, now be performed using only one laser unit, but also small-quantity production becomes feasible.
4. BM encapsulant film for Mini LED displays
With the technology which Shin-Etsu Chemical has developed of efficiently debonding the support substrate without forming tether, going forward, it is expected that Mini LED chips also will rapidly become thinner as a result of the eliminating of the sapphire support substrate.
Shin-Etsu Polymer, a Shin-Etsu Group company, has developed a film-type black matrix (BM) encapsulant film for Mini LED display applications and it is going forward with customers’ sample evaluations.
This material, in addition to improving the Mini LED display’s contrast, it also performs the function of protecting Mini LED component parts from damage or unclean substances.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005461/en/
Contact information
For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-6812-2340, or from outside Japan: 81-3-6812-2340
Fax: 03-6812-2341, or from outside Japan: 81-3-6812-2341
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
